LOCUS BIOSCIENCES INC - ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY
Key Details
Description
ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY
Context & Analysis
On Feb 19, 2026, Department of Health and Human Services obligated $3,318,955 to LOCUS BIOSCIENCES INC for advance a novel therapeutic to a first-in-human clinical study. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition with 16 offers received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in MORRISVILLE, NC. The contract is scheduled through Feb 7, 2029. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.